Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06608238 · ClinicalTrials.gov registry record · Phase 2
The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma
A Phase 2 study of Nodular Basal Cell Carcinoma, sponsored by SkinJect.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 6
- Study locations
NCT06608238 is a Phase 2 study of Nodular Basal Cell Carcinoma that is actively recruiting participants, run by SkinJect. The registered enrollment target is 60 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT06608238, a Phase 2 study of Nodular Basal Cell Carcinoma, is actively recruiting participants, sponsored by SkinJect.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 6
- Study locations
Study Summary
The goal of the study is to learn about the safety and how effective two different strengths of D-MNA compared to a placebo (a look-alike substance that contains no drug) in the treatment of nodular basal cell skin cancer
Conditions Studied
Interventions
- OTHER Placebo
- DRUG D-MNA 200 mcg
- DRUG D-MNA 100 mcg
Study Locations (6)
California
- Site #4 - Fresno
- Site #6 - San Diego
Illinois
- Site #1 - Rolling Meadows
Louisiana
- Site #5 - Mandeville
New Jersey
- Site #3 - Highlands
Tennessee
- Site#2 - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2025-06-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06608238
The ClinicalTrials.gov registry entry for NCT06608238 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SkinJect, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nodular Basal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06608238 reports 6 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06608238 about?
NCT06608238 is a clinical study titled "The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma". The goal of the study is to learn about the safety and how effective two different strengths of D-MNA compared to a placebo (a look-alike substance that contains no drug) in the treatment of nodular basal cell skin cancer
What is the current status of trial NCT06608238?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-09-03. Estimated completion is 2025-06-02.
What conditions does trial NCT06608238 study?
This clinical trial studies the following conditions: Nodular Basal Cell Carcinoma.
What interventions are being tested in trial NCT06608238?
The interventions under investigation include: Placebo (OTHER), D-MNA 200 mcg (DRUG), D-MNA 100 mcg (DRUG).
Who is sponsoring clinical trial NCT06608238?
This trial is sponsored by SkinJect, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06608238 being conducted?
This trial has 6 study locations across California, Illinois, Louisiana, New Jersey, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nodular Basal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.